Adalimumab (ADA), is a fully human anti-TNF (Tumor Necrosis Factor α) monoclonal antibody [1] used for the treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease (CD), ulcerative colitis (UC), chronic psoriasis, hidradenitis suppurativa, juvenile idiopathic arthritis, and uveitis [2]. Here, TNF is linked to psoriatic arthritis.